Sign inCreate account

Report workspace tools

NCT02677246WITHDRAWNanonymous

Phase 1 Trial of Denosumab for Prevention of Bone Complications After Allogenic Hematopoietic Stem Cell Transplantation in Children

Sponsor

Source record

St. Justine's Hospital

Phase

Source record

Phase 1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Bone complications after bone marrow transplantation in children

Indication / condition

AI-normalized

Disorder Related to Bone Marrow Transplantation

Intervention

Source record

Denosumab

Source & freshness

Source record

NCT ID

NCT02677246

Original source

ClinicalTrials.gov

Source last updated

Sep 06, 2018

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02677246

Title

Phase 1 Trial of Denosumab for Prevention of Bone Complications After Allogenic Hematopoietic Stem Cell Transplantation in Children

Sponsor

St. Justine's Hospital

Status

WITHDRAWN

Phase

Phase 1

Condition raw

Disorder Related to Bone Marrow Transplantation

Condition normalized

Disorder Related to Bone Marrow Transplantation

Modality raw

Disorder Related to Bone Marrow Transplantation

Modality normalized

monoclonal antibody

Target raw

Bone complications after bone marrow transplantation in children

Target normalized

Bone complications after bone marrow transplantation in children

Interventions

Denosumab

Public preview

Source record

This clinical trial aimed to evaluate the safety and efficacy of Denosumab in preventing bone complications in pediatric patients following allogenic hematopoietic stem cell transplantation. The study was conducted by St. Justine's Hospital and was designed to assess the maximum tolerable dose and biological activity of Denosumab, a drug that inhibits bone resorption.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 1 Trial of Denosumab for Prevention of Bone Complications After Allogenic Hematopoietic Stem Cell Transplantation in Children

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02677246

Status

WITHDRAWN

Phase

Phase 1

Sponsor

St. Justine's Hospital

Executive brief

Investment-Ready Snapshot

This clinical trial aimed to evaluate the safety and efficacy of Denosumab in preventing bone complications in pediatric patients following allogenic hematopoietic stem cell transplantation. The study was conducted by St. Justine's Hospital and was designed to assess the maximum tolerable dose and biological activity of Denosumab, a drug that inhibits bone resorption.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 06, 2018
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02677246

Indication

Disorder Related to Bone Marrow Transplantation

Modality

monoclonal antibody

Target

Bone complications after bone marrow transplantation in children

Intervention

Denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.